A phase 3 study to determine the efficacy and safety oflenalidomide combined with melphalan and prednisone in patients= 65 years with newly diagnosed multiple myeloma (NDMM)

MPR-R elicited higher and more rapid responses resulting in prolonged PFS. Additionally, lenalidomide taken continuously versus a fixed number of cycles significantly extended PFS with incidence of AEs comparable to placebo during the continuous therapy period. These data suggest that continuous use of lenalidomide is superior to regimens of limited duration and provides sustained disease control to patients with NDMM.